My research focuses on research in epidemiology and outcomes of inflammatory bowel diseases and development of personalized medicine approach.
Research & Clinical Trials
Researching mucosal immunology and inflammatory bowel disease.
The CSIBD Clinical Core provides an infrastructure to facilitate the translation of basic research findings into a clinical setting.
The Corcoran laboratory focuses on developing new and effective therapies for gastrointestinal cancers, such as colorectal and pancreatic cancers, by targeting the specific survival signals that are active in a given patient's cancer.
Our laboratory seeks to gain new insights into the molecular pathogenesis of tumors of the GI tract. Our particular areas of interest are colon cancer, neuroendocrine tumors, angiogenesis, hypoxia, hereditary cancers, and genetic instability. We seek to identify molecular targets that can ultimately guide therapeutic strategies.
Our laboratory has been involved in uncovering the mechanisms by which hepatitis viruses, particularly hepatitis C, persist in the liver and cause liver damage.
Dr. Dienstag is an experienced clinical investigator in the area of viral hepatitis (trials of antiviral therapies for chronic hepatitis B and C). Between 2000 and 2010, he was the site-PI of a national trial of maintenance antiviral therapy for patients refractory to treatment for chronic hepatitis C, the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial.
The Human Genetics and Microbiome Core strives to provide the CSIBD community with the power of current and emerging ‘omics technology to accelerate research on multiple aspects of IBD and other digestive diseases.
Our core provides CSIBD with cost-effective access to crucial instruments, reagents, protocols, training and education.
At the Mass General Weight Center, we believe that treatments for obesity that are safe and effective will be discovered only through ongoing research to find the answers to these and other questions.
Learn More About Us
Discoveries into the underlying mechanisms of gastrointestinal diseases and new treatment approaches are facilitated by a large research base within Massachusetts General Hospital and the NIH-funded Center for the Study of Inflammatory Bowel Disease.